Antoni Ribas, MD, PhD: For certain cancers where we know it can only work in a specific situation that has a specific marker, having a companion diagnostic makes a lot of sense. You want to select ...
Many U.S. hospitals using predictive models are not evaluating their tools internally for accuracy, and fewer still are evaluating them for potential biases, according to a study published in the most ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Add Yahoo as a preferred source to see more of our stories on Google. MiraDx's Prostox Standard test aims to identify localised prostate cancer patients who may experience long-term California-based ...
Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast CTX, a new predictive capability within its Ataraxis Breast ...
CYP2D6 polymorphism in Chinese breast cancer population. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results